feb 8 2012
- Health Canada Approves Skin Cancer Imaging System, MoleMate™
- has received approval from Health Canada, and is immediately available and in stock for all Canadian physicians, joining their colleagues in Europe, the UK, Australia, and the US
- In the last quarter of 2011 we began selling into the US market which is estimated to be a $1 Billion dollar opportunity, based on retail prices between $5-$10K per system," stated Steve Guillen, President & CEO at MedX Health Corp

feb 29 2012
- Senior Management Agree to Debt Settlement Of $1.3 Million at Significant Prices Over Market
- The debt settlement will allow the Company to restructure $1,313,031 of outstanding debt (approximately 25% of the company debt) through the issuance of 3,209,633 shares; one third (1/3) at
.25, 1/3 at
.50, and 1/3 at
.75.
- This significant debt reduction allows us to improve our financial profile rapidly, without the dilution and costs normally associated with this type of transaction

mar 5 2012
- Skin Cancer Imaging with MoleMate™ Accelerates New Revenue Growth Strategy Via Entry Into Multiple Hundred Million Dollar Markets and On-Line Services
- Strong sales in Q4 2011, led by MoleMate; best quarter in over three (3) years
- by offering a web based solution, via 'cloud' technology, we can lower the initial cost to physicians, as physicians pay monthly service fees, creating an on-going revenue stream for MedX from each device sold.
- The combined markets in Europe, Canada, Australia, and the US is worth over $200 Million in net device sales (Zach's Equity Research), and the opportunity via 'cloud' technology for recurring revenue could be worth millions of dollars every year in this emerging market
- The worldwide advanced wound care market (burns, diabetic foot ulcers and bed sores) is estimated at $5 Billion (Global Industry Analysts, Inc.) and the market potential using the MedX platform technology may be worth hundreds of millions of dollars

mar 9 2012
- Skin Cancer - The Most Common Form of Cancer
- Among the sophisticated equipment used by University of California Irvine Melanoma Center physicians is a SIMSYS-MoleMate SIAscope, one of the most advanced melanoma imaging systems in the world
- Nearly 800,000 Americans are living with a history of melanoma and 13 million Americans are living with a history of non-melanoma skin cancer

mar 15 2012
- President and CEO, Steve Guillen reviewed the impact that SIAscopy has already made on the Company and highlighted the expected opportunities in the future
- Key R&D partners in Proctor & Gamble and Unilever were acknowledged
- Broad worldwide patent portfolio; includes 9 core patents that have been granted throughout the world
-Immediate availability in Canada, the US, and other locations around the world, and that Schuco in the UK and EBOS in Australia will be key distributors in 2012, with ScreenCancer expanding the screening centers in Europe and Australia

mar 20 2012
- MedX Health Corp. Enters China - One of the World's Largest and Fastest Growing Medical Device Markets
- we expect China to quickly become our largest customer and grow dramatically in the future.
- In 2009, the Chinese government committed 850 billion yuan (US$124 billion) to develop the country's healthcare system over a three-year period
- The prospects for medical device spending is huge; the government has committed heavily in the construction of thousands of hospitals, healthcare centers, clinics and this will inevitably lead to spending on capital goods, most notably medical devices, equipment and furniture at an unprecedented rate in a relatively short space of time. Espicom estimates medical device market growth to be in the region of 13.1%; one of the fastest growing markets in the world. High rates of growth are not uncommon in the Asian region, but on the back of a huge market size, China's growth is particularly pronounced

mar 23 2012
- Skin Cancer Imaging with MoleMate Featured at American Academy of Dermatology Meeting
- MoleMate and its more robust software, SIMSYS, gained the attention of the dermatologists in attendance at the American Academy of Dermatology's 70^th Annual Meeting, the world's largest, most comprehensive dermatologic educational event, which was held March 17-20, 2012, in San Diego, California
- At this meeting, dermatologists had a chance to compare MoleMate to recent market entries, and they told us that other devices that would help them identify skin cancers early are more costly to acquire and use, and do not offer the range of feedback on all moles that is possible with MoleMate
-the integration of Mole Mapping with MoleMate later in the year would be an additional advantage and continue to differentiate the MedX products in this new emerging market